Indeed, daratumumab, a novel therapeutic human CD38 antibody, and humanized monoclonal CD38 antibody (SAR650984) are currently under clinical use for patients with myeloma without severe side effect.27 The concomitant use of an anti-CD38 antibody and ATRA may clinically orchestrate cytotoxicity against AML cells in patients with AML. Here, CD38 is linked to plasma cell myeloma.